ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Poliovirus Vaccine, Oral

Also written as “Polio Sabin™”, “Oral bivalent types 1 and 3; Poliomyelitis Vaccine (OPV)” and “sIPV+bOPV”.

Its studies are mostly in Streptococcal Infections · Poliomyelitis · Tuberculosis · Hepatitis B · Rotavirus Infections, led by 3 companies.

Drug pagePoliovirus Vaccine, Oral: every studyAll 12 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Oct 19, 20076 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
GlaxoSmithKlineits history only40 open or runningphase 3since Oct 19, 2007Oct 19, 2007none ahead
Beijing Minhai Biotechnologyits history only10 open or runningphase 3since Dec 12, 2024Dec 12, 2024none ahead
Merck10 open or runningphase 3since Aug 12, 2005Aug 12, 2005none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Merck only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 12, 2005First study: phase 3 study in Rotavirus InfectionsFirst studyNCT00130832 · 735 enrolled

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

Studies

The one study Merck leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT00130832Rotavirus Infections3CompletedJul 2006735

How it is read

Names in the registry

  • “Polio Sabin™”, 2 entries
  • “Oral bivalent types 1 and 3; Poliomyelitis Vaccine (OPV)”, 1 entry
  • “sIPV+bOPV”, 1 entry
  • “Polio Sabin”, 1 entry
  • “bOPV”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.